Clinical indicators of immune restoration following highly active antiretroviral therapy

Clinical Infectious Diseases

Volumn 34, Issue 2, 2001, Pages 224-233

  Cooney, Elizabeth L ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ANTIRETROVIRUS AGENT; AZITHROMYCIN; HEPATITIS A VACCINE; HEPATITIS B VACCINE; NONSTEROID ANTIINFLAMMATORY AGENT; PNEUMOCOCCUS VACCINE; STEROID; TETANUS TOXOID;

ARTICLE; CHICKENPOX; CLINICAL TRIAL; CREUTZFELDT JAKOB DISEASE; CRYPTOCOCCOSIS; CYTOMEGALIC INCLUSION BODY DISEASE; DELAYED HYPERSENSITIVITY; HEPATITIS A; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; KAPOSI SARCOMA; LYMPHOCYTE COUNT; MYCOBACTERIOSIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; T LYMPHOCYTE SUBPOPULATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HUMANS; IMMUNE SYSTEM;

EID: 0037079918     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/323898     Document Type: Article

References (43)

1. Rosenberg ES, Walker BD. HIV type 1-specific helper T cells: a critical host defense. AIDS Res Hum Retroviruses 1998; 14:S143-7.
2. Musey L, Krieger J, Hughes J, et al. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J Infect Dis 1999; 180:278-84.
3. + cell numbers and clinical staging. J Clin Invest 1989; 84:1892-9.
4. Nagy-Agren SE, Cooney EL. Interleukin-12 enhancement of antigen-specific lymphocyte proliferation correlates with stage of human immunodeficiency virus infection. J Infect Dis 1999; 179:493-6.
5. + T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-6.
6. Li TS, Tubiana R, Katlama C, et al. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351:1682-6.
7. Connick E, Lederman MM, Kotzin BL, et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis 2000; 181:358-63.
8. Rinaldo CR, Liebmann JM, Huang X-L, et al. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. J Infect Dis 1999; 179:329-36.
9. + T cell responses associated with control of viremia. Science 1997; 278:1447-50.
10. Malhotra U, Berrey MM, Huang Y, et al. Effect of combination therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis 2000; 181:121-31.
11. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999; 5:518-25.
12. + T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. J Infect Dis 2000; 181:1264-72.
13. Blankson JN, Gallant JE, Siliciano RF. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1 infected patients with immune reconstitution. J Infect Dis 2001; 183:657-61.
14. Havlir DV, Schrier RD, Torriani FJ, et al. Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects. J Infect Dis 2000; 182:1658-63.
15. + T lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998; 4:953-6.
16. Valdez H, Smith KY, Landay A, et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor containing regimen: ACTG 375 team. AIDS Clinical Trials Group. AIDS 2000; 14:11-21.
17. Mussini C, Pezzotti P, Govoni A, et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasrnic encephalitis in human immunodeficiency virus type-1-infected patients: the changes in opportunistic prophylaxis study. J Infect Dis 2000; 181:1635-42.
18. Yangco BG, Von Bargen JC, Moorman AC, et al. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. Ann Intern Med 2000; 132:201-5.
19. Furrer H, Egger MJ, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. N Engl J Med 1999; 340:1301-6.
20. Schneider MM, Borleffs JCC, Stolk RP, et al. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. Lancet 1999; 353:201-3.
21. Weverling GJ, Mocroft AM, Ledergerber B, et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet 1999; 353:1293-8.
22. Lopez Bernaldo De Quiros JC, Miro JM, Pena JM, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. N Engl J Med 2001; 344:159-67.
23. Kirk O, Lundgren JD, Pedersen C, et al. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? AIDS 1999; 13:1647-51.
24. El Sadr WM, Burman WJ, Grant LB, et al. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. N Engl J Med 2000; 342:1085-92.
25. + cell count. Ann Intern Med 2000; 133:493-503.
26. Furrer H, Telenti AM, Rossi M, et al. Discontinuing or withholding prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study. AIDS 2000; 14:1409-12.
27. Whitcup SM, Fortin E, Nussenblatt RB, et al. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis. JAMA 1997; 277:1519-20.
28. McDonald CJ, Torriani FJ, Morse LS, et al. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998; 177:182-7.
29. Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998; 177:1080-3.
30. + counts. Ophthalmology 1998; 105:1259-64.
31. Jabs DA, Bolton SG, Dunn JP, et al. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol 1998; 126:817-22.
32. Di Perri G, Vento S, Mazzi R, et al. Recovery of long-term natural protection against reactivation of CMV retinitis in AIDS patients responding to highly active antiretroviral therapy. J Infect 1999; 39:193-7.
33. Whitcup SM, Fortin E, Lindblad AS, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and CMV retinitis. JAMA 1999; 282:1533-7.
34. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997; 349:1443-5.
35. Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998; 351:252-5.
36. + T cell counts and recurrent retinitis. J Infect Dis 2001; 183:1285-9.
37. Johnson SC, Benson CA, Johnson DW, et al. Recurrences of cytomegalovirus retinitis in a human immunodeficiency virus-infected patient, despite potent antiretroviral therapy and apparent immune reconstitution. Clin Infect Dis 2001; 32:815-9.
38. DeSimone JA, Pomerantz RJ, Babinchak TJ, et al. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133:447-54.
39. Woods ML, MacGinley R, Eisen DP, et al. HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection. AIDS 1998; 12:1491-4.
40. Collazos J, Mayo J, Martinez E, et al. Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients. AIDS 1999; 13:1426-8.
41. Karavellas MP, Plummer DJ, Macdonald JC, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 1999; 179:697-700.
42. Martinez-Marcos FJ, Lopez-Cortes LF, Pachon J, et al. Comparison of two methods for the assessment of delayed-type hypersensitivity skin responses in patients with human immunodeficiency virus infection. Clin Infect Dis 1998; 26:1330-4.
43. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987; 317:185-91.